These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 24416811)

  • 1. [Treatment of relapses of multiple sclerosis (a review)].
    Brkovich RR; Totolian NA; Sokolov AIu; Ignatov IuD; Skoromets AA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(10 Pt 2):69-77. PubMed ID: 24416811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of acute relapses in multiple sclerosis.
    Berkovich R
    Neurotherapeutics; 2013 Jan; 10(1):97-105. PubMed ID: 23229226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Multiple Sclerosis Relapse.
    Berkovich RR
    Continuum (Minneap Minn); 2016 Jun; 22(3):799-814. PubMed ID: 27261683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Multiple Sclerosis Relapses.
    Repovic P
    Continuum (Minneap Minn); 2019 Jun; 25(3):655-669. PubMed ID: 31162310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of patients who have relapses in multiple sclerosis.
    Williams G
    Br J Nurs; 2004 Sep 23-Oct 13; 13(17):1012-6. PubMed ID: 15549010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of multiple sclerosis: the state of the art.
    Karussis D
    BioDrugs; 2013 Apr; 27(2):113-48. PubMed ID: 23423844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple sclerosis relapses are associated with increased fatigue and reduced health-related quality of life - A post hoc analysis of the TEMSO and TOWER studies.
    Mäurer M; Comi G; Freedman MS; Kappos L; Olsson TP; Wolinsky JS; Miller AE; Dive-Pouletty C; Bozzi S; O'Connor PW
    Mult Scler Relat Disord; 2016 May; 7():33-40. PubMed ID: 27237754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Hersh CM; Cohen JA
    Immunotherapy; 2014; 6(3):249-59. PubMed ID: 24762071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Plasma immunoadsorption treatment of malignant multiple sclerosis with severe and prolonged relapses].
    de Andrés C; Anaya F; Giménez-Roldán S
    Rev Neurol; 2000 Apr 1-15; 30(7):601-5. PubMed ID: 10859735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The incomplete nature of multiple sclerosis relapse resolution.
    Lublin FD
    J Neurol Sci; 2007 May; 256 Suppl 1():S14-8. PubMed ID: 17337274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort.
    Correia I; Ribeiro JJ; Isidoro L; Batista S; Nunes C; Macário C; Borges C; Tomaz J; Sousa L
    Mult Scler Relat Disord; 2018 Jan; 19():148-152. PubMed ID: 29241141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients characteristics influencing the longitudinal utilization of steroids in multiple sclerosis--an observational study.
    Rommer PS; Buckow K; Ellenberger D; Friede T; Pitschnau-Michel D; Fuge J; Stüve O; Zettl UK;
    Eur J Clin Invest; 2015 Jun; 45(6):587-93. PubMed ID: 25868705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The costs and consequences of multiple sclerosis relapses: a managed care perspective.
    Morrow TJ
    J Neurol Sci; 2007 May; 256 Suppl 1():S39-44. PubMed ID: 17362995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of natalizumab vs fingolimod for the treatment of relapsing-remitting multiple sclerosis: analyses in Sweden.
    O'Day K; Meyer K; Stafkey-Mailey D; Watson C
    J Med Econ; 2015 Apr; 18(4):295-302. PubMed ID: 25422991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
    Parfenov V; Du Pasquier R; Schluep M
    Neurologist; 2015 Jun; 19(6):155-7. PubMed ID: 26075469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The management of pediatric multiple sclerosis.
    Yeh EA; Weinstock-Guttman B
    J Child Neurol; 2012 Nov; 27(11):1384-93. PubMed ID: 22914373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progressive Multiple Sclerosis.
    Willis MA; Fox RJ
    Continuum (Minneap Minn); 2016 Jun; 22(3):785-98. PubMed ID: 27261682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Differential influence of immune therapy on relapses and progression in multiple sclerosis: interpretation and therapeutic consequences].
    Kornhuber ME; Presek P; Zierz S
    Fortschr Neurol Psychiatr; 2005 Mar; 73(3):143-9. PubMed ID: 15747223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early relapses, onset of progression, and late outcome in multiple sclerosis.
    Scalfari A; Neuhaus A; Daumer M; Deluca GC; Muraro PA; Ebers GC
    JAMA Neurol; 2013 Feb; 70(2):214-22. PubMed ID: 23407713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.